DDInter624 DDInter1508
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Prasugrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Prasugrel
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is associated with {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Prasugrel
Efavirenz {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is regulated by {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Prasugrel
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Nevirapine
Nevirapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Efavirenz {u} (Compound) downregulates {v} (Gene) PFN1
PFN1 {u} (Gene) is downregulated by {v} (Compound) Fluvoxamine
Fluvoxamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prasugrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Neoplasm malignant
Neoplasm malignant {u} (Side Effect) is caused by {v} (Compound) Venlafaxine
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prasugrel
Efavirenz {u} (Compound) causes {v} (Side Effect) Neoplasm malignant
Neoplasm malignant {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prasugrel
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Efavirenz (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Efavirenz (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Efavirenz (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is associated with ALB (Gene) and ALB (Gene) is bound by Prasugrel (Compound)
Efavirenz (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is regulated by ALB (Gene) and ALB (Gene) is bound by Prasugrel (Compound)
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Nevirapine (Compound) and Nevirapine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Efavirenz (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is downregulated by Fluvoxamine (Compound) and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Efavirenz (Compound) causes Neoplasm malignant (Side Effect) and Neoplasm malignant (Side Effect) is caused by Venlafaxine (Compound) and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Efavirenz (Compound) causes Neoplasm malignant (Side Effect) and Neoplasm malignant (Side Effect) is caused by Ticagrelor (Compound) and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel